Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Jade Biosciences, Inc.AVTE · Entity 4757 | CHIEF SCIENTIFIC OFFICER | February 05, 2024 | February 07, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Jade Biosciences, Inc.
Report date February 05, 2024 · Filed February 07, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,609 |
Ending reported balance
After 2024-02-05 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2024-02-05 · Exercise / conversion · Acquired 1,400 · Balance 3,009 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2023. Row 2 · 2024-02-05 · Exercise / conversion · Acquired 3,200 · Balance 6,209 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2023. Row 3 · 2024-02-05 · Sale · Disposed 4,600 · Balance 1,609 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2023. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.16 to $18.075, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.74 · Expires 2030-09-03 | Direct | 13,308 |
Reported balance
After 2024-02-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-02-05 · Exercise / conversion · Disposed 900 · Balance 13,308 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2023. F3: A total of 24,108 shares subject to an employee stock option were granted on September 4, 2020, with 25% of this option vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.74 · Expires 2030-09-03 | Direct | 9,088 |
Reported balance
After 2024-02-05 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-02-05 · Exercise / conversion · Disposed 500 · Balance 9,088 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2023. F4: A total of 14,488 shares subject to an employee stock option were granted on September 4, 2020, with 25% of this option vested on June 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.14 · Expires 2031-04-01 | Direct | 10,894 |
Reported balance
After 2024-02-05 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-02-05 · Exercise / conversion · Disposed 500 · Balance 10,894 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2023. F5: A total of 16,294 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on May 2, 2021. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.14 · Expires 2031-04-01 | Direct | 34,908 |
Reported balance
After 2024-02-05 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-02-05 · Exercise / conversion · Disposed 1,200 · Balance 34,908 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2023. F6: A total of 49,908 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on July 4, 2021. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.14 · Expires 2031-04-01 | Direct | 41,732 |
Reported balance
After 2024-02-05 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2024-02-05 · Exercise / conversion · Disposed 1,500 · Balance 41,732 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2023. F7: A total of 59,732 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on July 4, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2023.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.16 to $18.075, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3: A total of 24,108 shares subject to an employee stock option were granted on September 4, 2020, with 25% of this option vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.
F4: A total of 14,488 shares subject to an employee stock option were granted on September 4, 2020, with 25% of this option vested on June 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.
F5: A total of 16,294 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on May 2, 2021.
F6: A total of 49,908 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on July 4, 2021.
F7: A total of 59,732 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on July 4, 2021.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 05, 2022 Filed Dec 7, 2022 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 2,250 | $17.38 | $39,114.00 |
DisclosureSEC source: 0001415889-22-012183 · form4-12072022_061201.xml · nonDerivative · entry 3 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,609 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.00 to $17.91, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| December 05, 2022 Filed Dec 7, 2022 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 1,600 | $2.14 | $3,424.00 |
DisclosureSEC source: 0001415889-22-012183 · form4-12072022_061201.xml · nonDerivative · entry 2 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,859 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. Read SEC document |
| December 05, 2022 Filed Dec 7, 2022 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 650 | $1.74 | $1,131.00 |
DisclosureSEC source: 0001415889-22-012183 · form4-12072022_061201.xml · nonDerivative · entry 1 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,259 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. Read SEC document |
| November 07, 2022 Filed Nov 9, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 750 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-22-011246 · form4-11092022_051110.xml · derivative · entry 11 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,732 Underlying: Common Stock · 750 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. F10 · derivative.exercise_date: A total of 59,732 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on July 4, 2021. Read SEC document |
| November 07, 2022 Filed Nov 9, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 650 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-22-011246 · form4-11092022_051110.xml · derivative · entry 10 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,308 Underlying: Common Stock · 650 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. F9 · derivative.exercise_date: A total of 49,908 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on July 4, 2021. Read SEC document |
| November 07, 2022 Filed Nov 9, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 200 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-22-011246 · form4-11092022_051110.xml · derivative · entry 9 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,494 Underlying: Common Stock · 200 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. F8 · derivative.exercise_date: A total of 16,294 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on May 2, 2021. Read SEC document |
| November 07, 2022 Filed Nov 9, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 200 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001415889-22-011246 · form4-11092022_051110.xml · derivative · entry 8 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,688 Underlying: Common Stock · 200 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. F7 · derivative.exercise_date: A total of 14,488 shares subject to an employee stock option were granted on September 4, 2020, with 25% of this option vested on June 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| November 07, 2022 Filed Nov 9, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 450 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001415889-22-011246 · form4-11092022_051110.xml · derivative · entry 7 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,308 Underlying: Common Stock · 450 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. F6 · derivative.exercise_date: A total of 24,108 shares subject to an employee stock option were granted on September 4, 2020, with 25% of this option vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| November 07, 2022 Filed Nov 9, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 215 | $20.29 | $4,363.00 |
DisclosureSEC source: 0001415889-22-011246 · form4-11092022_051110.xml · nonDerivative · entry 6 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,609 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.21 to $20.51, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| November 07, 2022 Filed Nov 9, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 1,430 | $19.82 | $28,346.89 |
DisclosureSEC source: 0001415889-22-011246 · form4-11092022_051110.xml · nonDerivative · entry 5 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,824 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.15 to $20.14, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| November 07, 2022 Filed Nov 9, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 155 | $18.02 | $2,793.57 |
DisclosureSEC source: 0001415889-22-011246 · form4-11092022_051110.xml · nonDerivative · entry 4 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,254 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.70 to $18.62, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| November 07, 2022 Filed Nov 9, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 450 | $17.09 | $7,690.95 |
DisclosureSEC source: 0001415889-22-011246 · form4-11092022_051110.xml · nonDerivative · entry 3 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,409 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.67 to $17.41, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| November 07, 2022 Filed Nov 9, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 1,600 | $2.14 | $3,424.00 |
DisclosureSEC source: 0001415889-22-011246 · form4-11092022_051110.xml · nonDerivative · entry 2 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,859 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. Read SEC document |
| November 07, 2022 Filed Nov 9, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 650 | $1.74 | $1,131.00 |
DisclosureSEC source: 0001415889-22-011246 · form4-11092022_051110.xml · nonDerivative · entry 1 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,259 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. Read SEC document |
| October 05, 2022 Filed Oct 7, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 750 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-22-010412 · form4-10072022_051021.xml · derivative · entry 9 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,482 Underlying: Common Stock · 750 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. F8 · derivative.exercise_date: A total of 59,732 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on July 4, 2021. Read SEC document |
| October 05, 2022 Filed Oct 7, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 650 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-22-010412 · form4-10072022_051021.xml · derivative · entry 8 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,958 Underlying: Common Stock · 650 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. F7 · derivative.exercise_date: A total of 49,908 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on July 4, 2021. Read SEC document |
| October 05, 2022 Filed Oct 7, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 200 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-22-010412 · form4-10072022_051021.xml · derivative · entry 7 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,694 Underlying: Common Stock · 200 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. F6 · derivative.exercise_date: A total of 16,294 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on May 2, 2021. Read SEC document |
| October 05, 2022 Filed Oct 7, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 200 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001415889-22-010412 · form4-10072022_051021.xml · derivative · entry 6 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,888 Underlying: Common Stock · 200 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. F5 · derivative.exercise_date: A total of 14,488 shares subject to an employee stock option were granted on September 4, 2020, with 25% of this option vested on June 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| October 05, 2022 Filed Oct 7, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 450 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001415889-22-010412 · form4-10072022_051021.xml · derivative · entry 5 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,758 Underlying: Common Stock · 450 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. F4 · derivative.exercise_date: A total of 24,108 shares subject to an employee stock option were granted on September 4, 2020, with 25% of this option vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| October 05, 2022 Filed Oct 7, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 191 | $16.22 | $3,097.64 |
DisclosureSEC source: 0001415889-22-010412 · form4-10072022_051021.xml · nonDerivative · entry 4 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,609 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.21 to $16.41, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 05, 2022 Filed Oct 7, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 2,059 | $15.71 | $32,348.95 |
DisclosureSEC source: 0001415889-22-010412 · form4-10072022_051021.xml · nonDerivative · entry 3 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,800 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.13 to $16.11, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 05, 2022 Filed Oct 7, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 1,600 | $2.14 | $3,424.00 |
DisclosureSEC source: 0001415889-22-010412 · form4-10072022_051021.xml · nonDerivative · entry 2 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,859 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. Read SEC document |
| October 05, 2022 Filed Oct 7, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 650 | $1.74 | $1,131.00 |
DisclosureSEC source: 0001415889-22-010412 · form4-10072022_051021.xml · nonDerivative · entry 1 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,259 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. Read SEC document |
| September 06, 2022 Filed Sep 7, 2022 17:30 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 750 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001493152-22-025289 · ownership.xml · derivative · entry 8 NIVEN RALPH · CIK 0001168060 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,232 Underlying: Common Stock · 750 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. F6 · derivative.exercise_date: A total of 59,732 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on July 4, 2021. Read SEC document |
| September 06, 2022 Filed Sep 7, 2022 17:30 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 650 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001493152-22-025289 · ownership.xml · derivative · entry 7 NIVEN RALPH · CIK 0001168060 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,608 Underlying: Common Stock · 650 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. F5 · derivative.exercise_date: A total of 49,908 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on July 4, 2021. Read SEC document |
| September 06, 2022 Filed Sep 7, 2022 17:30 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 200 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001493152-22-025289 · ownership.xml · derivative · entry 6 NIVEN RALPH · CIK 0001168060 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,894 Underlying: Common Stock · 200 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. F4 · derivative.exercise_date: A total of 16,294 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on May 2, 2021. Read SEC document |
| September 06, 2022 Filed Sep 7, 2022 17:30 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 200 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001493152-22-025289 · ownership.xml · derivative · entry 5 NIVEN RALPH · CIK 0001168060 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,088 Underlying: Common Stock · 200 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. F3 · derivative.exercise_date: A total of 14,488 shares subject to an employee stock option were granted on September 4, 2020, with 25% of this option vested on June 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| September 06, 2022 Filed Sep 7, 2022 17:30 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 450 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001493152-22-025289 · ownership.xml · derivative · entry 4 NIVEN RALPH · CIK 0001168060 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,208 Underlying: Common Stock · 450 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. F2 · derivative.exercise_date: A total of 24,108 shares subject to an employee stock option were granted on September 4, 2020, with 25% of this option vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| September 06, 2022 Filed Sep 7, 2022 17:30 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 2,250 | $19.00 | $42,750.00 |
DisclosureSEC source: 0001493152-22-025289 · ownership.xml · nonDerivative · entry 3 NIVEN RALPH · CIK 0001168060 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,609 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. Read SEC document |
| September 06, 2022 Filed Sep 7, 2022 17:30 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 1,600 | $2.14 | $3,424.00 |
DisclosureSEC source: 0001493152-22-025289 · ownership.xml · nonDerivative · entry 2 NIVEN RALPH · CIK 0001168060 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,859 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. Read SEC document |
| September 06, 2022 Filed Sep 7, 2022 17:30 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 650 | $1.74 | $1,131.00 |
DisclosureSEC source: 0001493152-22-025289 · ownership.xml · nonDerivative · entry 1 NIVEN RALPH · CIK 0001168060 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,259 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. Read SEC document |
| August 18, 2022 Filed Aug 19, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 750 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001493152-22-023617 · ownership.xml · derivative · entry 8 NIVEN RALPH · CIK 0001168060 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,982 Underlying: Common Stock · 750 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. F7 · derivative.exercise_date: A total of 59,732 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on July 4, 2021. Read SEC document |
| August 18, 2022 Filed Aug 19, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 650 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001493152-22-023617 · ownership.xml · derivative · entry 7 NIVEN RALPH · CIK 0001168060 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,258 Underlying: Common Stock · 650 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. F6 · derivative.exercise_date: A total of 49,908 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on July 4, 2021. Read SEC document |
| August 18, 2022 Filed Aug 19, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 200 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001493152-22-023617 · ownership.xml · derivative · entry 6 NIVEN RALPH · CIK 0001168060 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,094 Underlying: Common Stock · 200 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. F5 · derivative.exercise_date: A total of 16,294 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on May 2, 2021. Read SEC document |
| August 18, 2022 Filed Aug 19, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 200 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001493152-22-023617 · ownership.xml · derivative · entry 5 NIVEN RALPH · CIK 0001168060 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,288 Underlying: Common Stock · 200 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. F4 · derivative.exercise_date: A total of 14,488 shares subject to an employee stock option were granted on September 4, 2020, with 25% of this option vested on June 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| August 18, 2022 Filed Aug 19, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 450 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001493152-22-023617 · ownership.xml · derivative · entry 4 NIVEN RALPH · CIK 0001168060 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,658 Underlying: Common Stock · 450 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. F3 · derivative.exercise_date: A total of 24,108 shares subject to an employee stock option were granted on September 4, 2020, with 25% of this option vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| August 18, 2022 Filed Aug 19, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 2,250 | $21.18 | $47,657.25 |
DisclosureSEC source: 0001493152-22-023617 · ownership.xml · nonDerivative · entry 3 NIVEN RALPH · CIK 0001168060 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,609 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.70 to $21.68, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 18, 2022 Filed Aug 19, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 1,600 | $2.14 | $3,424.00 |
DisclosureSEC source: 0001493152-22-023617 · ownership.xml · nonDerivative · entry 2 NIVEN RALPH · CIK 0001168060 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,859 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. Read SEC document |
| August 18, 2022 Filed Aug 19, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 650 | $1.74 | $1,131.00 |
DisclosureSEC source: 0001493152-22-023617 · ownership.xml · nonDerivative · entry 1 NIVEN RALPH · CIK 0001168060 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,259 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. Read SEC document |
| December 14, 2021 Filed Dec 16, 2021 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | GrantStock Option (Right to Buy) · Derivative | 65,433 | $0.00 Strike: $10.61 | $0.00 |
DisclosureSEC source: 0001493152-21-031751 · ownership.xml · derivative · entry 1 NIVEN RALPH · CIK 0001168060 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,433 Underlying: Common Stock · 65,433 shares Expires 2031-12-13 F1 · derivative.exercise_date: This option shall vest and become exercisable in 48 substantially equal monthly installments, with the first installment vesting on January 14, 2022. Read SEC document |
| June 29, 2021 Filed Jul 1, 2021 18:35 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | GrantStock Option (Right to Buy) · Derivative | 26,300 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0001104659-21-088385 · tm2121189-8_4seq1.xml · derivative · entry 3 NIVEN RALPH · CIK 0001168060 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,300 Underlying: Common Stock · 26,300 shares Expires 2031-06-28 F5 · derivative.exercise_date: This option shall vest and become exercisable in 48 substantially equal monthly installments, with the first installment vesting July 29, 2021. Read SEC document |
| April 02, 2021 Filed Jul 1, 2021 18:35 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | GrantStock Option (Right to Buy) · Derivative | 109,640 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001104659-21-088385 · tm2121189-8_4seq1.xml · derivative · entry 2 NIVEN RALPH · CIK 0001168060 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,640 Underlying: Common Stock · 109,640 shares Expires 2031-04-01 F1 · derivative.exercise_price: On June 22, 2021, the Issuer completed a one-for-3.1060103 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split. F2 · kind: This transaction occurred prior to the Issuer's initial public offering, and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3. F1 · shares: On June 22, 2021, the Issuer completed a one-for-3.1060103 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split. F4 · derivative.exercise_date: This option shall vest and become exercisable in 48 substantially equal monthly installments, with the first installment vesting on July 4, 2021. F1 · derivative.underlying_shares: On June 22, 2021, the Issuer completed a one-for-3.1060103 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split. F1 · balance_after: On June 22, 2021, the Issuer completed a one-for-3.1060103 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split. Read SEC document |
| April 02, 2021 Filed Jul 1, 2021 18:35 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | GrantStock Option (Right to Buy) · Derivative | 16,294 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001104659-21-088385 · tm2121189-8_4seq1.xml · derivative · entry 1 NIVEN RALPH · CIK 0001168060 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,294 Underlying: Common Stock · 16,294 shares Expires 2031-04-01 F1 · derivative.exercise_price: On June 22, 2021, the Issuer completed a one-for-3.1060103 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split. F2 · kind: This transaction occurred prior to the Issuer's initial public offering, and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3. F1 · shares: On June 22, 2021, the Issuer completed a one-for-3.1060103 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split. F3 · derivative.exercise_date: This option shall vest and become exercisable in 48 substantially equal monthly installments, with the first installment vested on May 2, 2021. F1 · derivative.underlying_shares: On June 22, 2021, the Issuer completed a one-for-3.1060103 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split. F1 · balance_after: On June 22, 2021, the Issuer completed a one-for-3.1060103 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.